Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Filings indexed 577 across all filing types
Latest filing 2026-05-22 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 98% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules, detailing changes in issued and treasury shares, including detailed on-market share repurchases and cancellation data. It is a report of the company buying back its own shares. This matches the “Transaction in Own Shares” category, code POS.
2026-05-22 English
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF CIRCULAR AND NOTICE OF ANNUAL GENERAL MEETING
Report Publication Announcement Classification · 97% confidence The document is a notification letter and reply form informing non-registered holders that the Company’s circular and notice of the Annual General Meeting (“Current Corporate Communication”) have been published online. It does not contain the actual AGM materials or financial data, but merely announces the publication of those documents and provides instructions on how to obtain printed copies. Under the “menu vs meal” rule, this is an announcement of a report’s publication, not the report itself. Therefore, it should be classified as a Report Publication Announcement (RPA).
2026-05-21 English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF CIRCULAR, NOTICE OF ANNUAL GENERAL MEETING AND PROXY FORM
Report Publication Announcement Classification · 92% confidence The document is a shareholder notification letter advising registered shareholders of the publication of the company’s circular, notice of Annual General Meeting and proxy form on its website and HKEXnews, and provides instructions for accessing or requesting printed copies. It does not contain the actual AGM materials or substantive financial content, but merely announces the availability of those materials. Under the “menu vs meal” rule, this is a report publication announcement rather than the report itself.
2026-05-21 English
PROXY FORM FOR ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 91% confidence The document is a proxy form for the Company’s Annual General Meeting, soliciting voting instructions from shareholders on resolutions, with instructions on how to appoint a proxy and return the form. This fits the definition of Proxy Solicitation & Information Statement (materials sent to shareholders to request votes for meetings).
2026-05-21 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal Notice of Annual General Meeting for Simcere Pharmaceutical Group Limited, listing resolutions to be considered, proxy appointment details, dividend and board re-election votes, and meeting logistics. It is sent to shareholders to provide information and solicit votes rather than the AGM presentation itself or an actual financial report. This fits the Proxy Solicitation & Information Statement category.
2026-05-21 English
(I) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE AND TO REPURCHASE SHARES; (II) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (III) PROPOSED DECLARATION AND PAYMENT OF FINAL DIVIDEND; (IV) PROPOSED RE
Proxy Solicitation & Information Statement Classification · 93% confidence The document is a shareholder circular containing detailed explanations of resolutions to be proposed at the Annual General Meeting, including granting mandates, re-election of directors, dividend declarations, auditor reappointments, amendments to the articles, and includes the notice of the AGM and proxy form. This is a classic proxy solicitation and information statement rather than the report itself. Therefore, it should be classified as a Proxy Solicitation & Information Statement (PSI).
2026-05-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.